Cost of prostate cancer surgery varies widely in the US

Cost of prostate cancer surgery varies widely in the U.S.

(HealthDay)—The open market cost of a radical prostatectomy (RP) varies widely in U.S. hospitals, according to research published in the March issue of Urology.

Scott C. Pate, M.D., of the University of Iowa in Iowa City, and colleagues conducted a of a cohort of 100 U.S. hospitals to solicit price information for RP. The authors used a caller profile of an uninsured 55-year-old man recently diagnosed with Gleason 3 + 4 prostatic adenocarcinoma.

The researchers found that 70 hospitals provided facility prices for RP averaging $34,720 ± 20,335 (range, $10,100 to $135,000). The facility cost for RP was significantly higher at academic centers compared with private hospitals. No significant differences in cost were observed according to region, population, or ranking. Only 10 percent of hospitals provided price information for surgeon and anesthesia fees (average, $8,280 ± 4,282; range, $4,028 to $18,720). Discounts on fees (average, 34 ± 16 percent; range 10 to 80 percent) for prompt payment were offered by 33 hospitals.

"Currently, it appears to be unacceptably difficult for men with prostate cancer without insurance to obtain prices for an RP procedure," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Prostate cancer surgery better at teaching hospitals

date Nov 07, 2011

Prostate cancer patients who undergo radical prostatectomy get better results at teaching hospitals than at non-academic medical institutions, according to the findings of an international study led by researchers at Henry ...

Thermal sensation spared in nerve-sparing prostatectomy

date Sep 13, 2012

(HealthDay)—Penile thermal sensory thresholds increase after non-nerve-sparing radical prostatectomy (RP) but not after the nerve-sparing procedure, according to a study published in the September issue ...

Recommended for you

Merck drug Keytruda effective against 3 cancers

date 2 hours ago

One of the hot new cancer immunotherapy drugs, Merck & Co.'s Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to three studies presented Sunday at the American Association for Cancer ...

DNA blood test detects lung cancer mutations

date Apr 17, 2015

Cancer DNA circulating in the bloodstream of lung cancer patients can provide doctors with vital mutation information that can help optimise treatment when tumour tissue is not available, an international group of researchers ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.